Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation

Blood Reviews

Volumn 19, Issue 6, 2005, Pages 289-300

  Blair, Allison ^a   Goulden, Nicholas J ^b   Libri, Nathan A ^a   Oakhill, Anthony ^b   Pamphilon, Derwood H ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b Royal Hospital for Children   (United Kingdom)

Author keywords

ALL; Immunotherapy; Stem cell transplantation

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MYELOBLASTIN; TUMOR ANTIGEN; ZINC FINGER PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CULTURE; CELL DIFFERENTIATION; CELL STIMULATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIETIC CELL; HUMAN; HYBRID CELL; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE FUNCTION; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

EID: 27644535985     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2004.09.002     Document Type: Article

References (89)

1. J.M. Chessells, C. Bailey, and S.M. Richards Intensification of treatment and survival in all children with acute lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia Lancet 345 1995 143 148
2. X. Thomas, C. Danaila, and Q.H. Le Long-term follow-up of patients with newly diagnosed adult lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period Leukemia 15 2001 1811 1822
3. A.J. Barrett, Horowitz, and R.C. Ash Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 79 1992 3067 3070
4. S.M. Davies, N.K.C. Ramsey, and R.J. Harker Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts Bone Marrow Transpl 13 1994 51 57
5. A. Green, E. Clarke, and L. Hunt Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome Blood 94 1999 2236 2246
6. L. Schwartzenberg, and G. Mathe White cell transfusions: six years experience Br J Haematol 17 1969 603 604
7. R.L. Powles, J. Russell, and T.S.A. Lister Immunotherapy for acute myelogenous leukaemia:a controlled clinical study 2 1/2 years after entry of the last patient Br J Cancer 35 1977 265 272
8. H.J. Kolb, J. Mittermuller, and C. Clemm Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant recipients Blood 76 1990 2462 2465
9. H.J. Kolb, C. Schmid, A.J. Barrett, and D.J. Schendel Graft-versus-Leukemia reactions in allogeneic chimeras Blood 103 2004 767 776
10. H.J. Kolb, A. Schattenberg, and J.G. Goldman Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation working Party Chronic Leukaemia Blood 86 1995 2041 2050
11. R.E. Clark, I.A. Dodi, and S.C. Hill Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein Blood 98 2001 2887 2893
12. L.C. Norbury, R.E. Clark, and S. Christmas B3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia B J Haematol 109 2000 616 621
13. S. Slavin, E. Naparstek, A. Nagler, A. Ackerstein, J. Kapelushnik, and R. Or Allogeneic cell therapy for relapsed leukemia after bone marow transplantation with donor peripheral blood lymphocytes Exp Haematol 23 1995 1553 1562
14. P. Bader, G. Duckers, and H. Kreyenberg Monitoring of donor cell chimerism for the detection of relapse and early immunotherapeutic Intervention in acute lymphoblastic leukemia Ann Haematol 81 Suppl 2 2002 S25 S27
15. F. Dazzi, R.M. Szydlo, and C. Craddock Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 95 2000 67 71
16. K.S. Peggs, K. Thomson, and D.P. Hart Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism and disease responses Blood 103 2004 1548 1556
17. C. Guglielmi, W. Arcese, and F. Dazzi Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose Blood 100 2002 397 405
18. Z. Zheng, M. Takahashi, and S. Aoki Expression patterns of costimulatory molecules on cells derived from human haematological maligencies J Exp Clin Cancer Res 17 1998 251 258
19. J. Banchereau, and R.M. Steinmanb Dendritic cells and the control of immunity Nature 392 1998 245 252
20. M. Cella, F. Facchetti, A. Lanzavecchia, and M. Colonna Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Th1 polarisation Nature Immunol 1 2000 305 310
21. P. Brossart, S. Wirths, W. Brugger, and L. Kanz Dendritic cells in cancer vaccines Exp Haematol 29 2001 1247 1255
22. G. Despars, and H.C. O'Neill A role for niches in the development of a multiplicity of dendritic cell subsets Exp Haematol 32 2004 235 243
23. A. Blair, A.W. Rowbottom, and S.J. Browne An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission Leukemia 15 2001 1596 1603
24. C.D.L. Reid The biology and clinical applications of dendritic cells Transf Med 8 1998 77
25. K. Tarte, G. Fiol, J.-.F. Rossi, and B. Klein Extensive characterisation of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and t cell activation during maturation in vitro Leukemia 14 2000 2182 2192
26. M. Mohty, D. Jarrossay, and M. Lafage-Pochitaloff Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment Blood 98 2001 3750 3756
27. J. Galea-Lauri, D. Darling, G. Mufti, P. Harrison, and F. Farzaneh Eliciting cytotoxic T lymphocytes against acute myeloid leukemia derived antigens: evaluation of dendritic cell-leukaemia cell hybrids and other antigen-loading strategies for dendritic cell based vaccination Cancer Immunol Immunother 51 6 2002 299 310
28. R. Spisek, P. Chevallier, and N. Morineau Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin Cancer Res 62 10 2002 2861 2868
29. Y. Osman, M. Takahashi, and Z. Zheng Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed wih tumor cell extracts Oncol Rep 6 5 1999 1057 1063
30. D. Pospisilova, J. Borovickova, and A. Polouckova Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia Cancer Immunol Immunother 51 2 2002 72 78
31. Y. Osman, M. Takahashi, and Z. Zheng Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemic immunotherapy J Exp Clin Cancer Res 18 1999 485 492
32. D. Montagna, R. Maccario, and E. Montini Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukaemia or myelodysplastic cells using both HLA-matched and partially matched donors Exp Hematol 31 2004 1031 1038
33. S. Shimokubo, S.-.I. Wakamatsu, and Y. Maeda Fusion of mature dendritic cells and human T-lymphotropic virus type 1 infected cell: its efficiency as an antigen-presenting cell Virology 301 2002 13 20
34. N. Raje, T. Hideshima, and F.E. Davies Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma Br J Haematol 125 2004 343 352
35. A. Kabler, G. Stuhler, and P. Walden Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nature Med 6 2000 332 336
36. A. Marten, S. Renoth, and T. Heinicke Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma Hum Gene Ther 14 5 2003 483 494
37. T.M. Westers, A.G. Stam, and R.J. Scheper Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia Cancer Immunol Immunother 52 2003 17 27
38. A. Cignetti, E. Bryant, B. Allione, A. Vitale, R. Foa, and M.A. Cheever CD34+ acute myeloid and lymphoid leukemia blasts can be induced to differentiate into dendritic cells Blood 94 1999 2048 2055
39. T. Kohler, R. Plettig, and W. Wetzstein Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells Stem Cells 18 2000 139 147
40. B.A. Choudhury, J.C. Liang, and E.K. Thomas Dendritic cells derived in vitro from acute myelogenous leukemia blast cells stimulate autologous, antileukemic T-cell responses Blood 93 1999 780 786
41. R.E. Brouwer, M. der Hoorn, H.C. Kluin-Nelemans, I.S. van Zebleran, R. Willemz, and J.H. Falkenburg The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses Human Immunol 61 2000 565 574
42. M. Mohty, D. Isnardon, and D. Blaise Identification of precursors of leukemic dendritic cells differentiated from patients with acure myeloid leukemia Leukemia 16 2002 2267 2274
43. S.P. Robinson, N. English, R. Jaju, L. Kearney, S.C. Knight, and C.D.L. Reid The in vitro generation of dendritic cels from blast cells in acute leukaemia Br J Haematol 103 1998 763 771
44. M. Hagihara, Y. Shimakura, and T. Tsuchiya The efficient generation of CD83 positive immunocompetent dendritic cells from CD14 positive acute myelomonocytic of monocytic leukemia cells in vitro Leuk Res 25 2001 249 258
45. T. Tsuchiya, M. Hagihara, and Y. Shimakura The generation of immunocomperent dendritic cells from CD 34 positive acute myeloid of lymphoid leukemia cells Int J Hematol 75 2002 55 62
46. B.D. Harrison, J.A. Adams, M. Briggs, M.L. Brereton, and J.A. Liu Yin Stimulation of autologous proliferative and cytotoxic T- cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia Blood 97 2001 2764 2771
47. A. Woiciechowsky, S. Regn, H.J. Kolb, and M. Roskrow Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia Leukemia 15 2001 246 255
48. C. Bello-Fernandez, J. Stasakova, and A. Renner Retrovirus-mediated IL-7 expression in leukemic dendritic cells generated from primary acute myelogenous leukemia enhances their functional properties Blood 101 2003 2184 2190
49. A.A. Cardoso, J.P. Veiga, and P. Ghia Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies Blood 10 1999 3531 3540
50. M. Hagihara, T. Tsuchiya, and O. Hyodo The in vitro generation of Ph1+ cytotoxic T lymphocytes using a specific 16 mer minor bcr-abl peptide Leuk Res 27 2003 253 257
51. S.R. Riddell, M. Murata, S. Bryant, and E.H. Warren Minor histocompatibility antigens-targets of graft versus leukemia responses Int J Hematol 76 2002 155 161
52. S. Slavin, A. Ackerstein, E. Naparstek, R. Or, and L. Weiss The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transpl 6 1990 155 161
53. R.H. Collins, O. Shpilberg, and W.R. Drobyski Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 1997 433 444
54. K. Azuma, S. Shichijo, Y. Maeda, and T. Nakatsura Mutated p53 protein gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site Cancer Res 63 4 2003 854 858
55. A. Van Elsas, H.W. Nijman, and C.E. van der Hinne Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201 Int J Cancer 61 1995 389 396
56. J.Y. Sun, D. Senitzer, S.J. Forman, S. Chatterjee, and K.K.J.M. Wong Identification of new MHC-restriction elements for presentation of the p120 (BCR-ABL) fusion region to human cytotoxic T lymphocytes Cancer Immunol Immunother 52 12 2003 761 770
57. Z. Berke, M.H. Andersen, and M. Pedersen Peptides spanning the junctional region of both the abl/bcr and bcr/abl fusion proteins bind common HLA class I molecules Leukemia 14 2000 419 426
58. M. Bocchia, P.A. Wentworth, and S. Southwood Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules Blood 85 1995 2680 2694
59. M. Bocchia, T. Koronstvit, and A. Xu Specific human cellular immunity to bcr-abl oncogene derived peptides Blood 87 1996 3587 3592
60. G.J. Bosch, A.M. Joosten, J.H. Kessler, C.J. Melief, and O.C. Leeksma Recognition of BCR-ABL positive leukemia blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide Blood 88 1996 3522 3527
61. J. Molldrem, S. Dermine, and K. Parker Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood 88 1996 2450 2457
62. J. Molldrem, E. Clave, and Y.Z. Jiang Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide derived preferentially inhibit chronic myeloid leukemia colony-forming units Blood 90 1997 2529 2534
63. J. Molldrem, P.P. Lee, and C. Wang Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nature Med 6 9 2000 1018 1023
64. K.M. Call, T. Glasser, and C.Y. Ito Isolation and characterization of a zinc finger polypeptide gene at the 11 Wilms' tumor locus Cell 60 1990 509 520
65. K. Inoue, H. Sugiyama, and H. Ogawa WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia Blood 84 1994 3071 3079
66. L. Bergmann, C. Miething, and U. Maurer High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome Blood 90 3 1997 1217 1225
67. H. Ohminami, M. Yasukawa, and S. Fujita HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocite clone specific for WT1 peptide Blood 95 2000 286 293
68. Y. Oka, and O.A. Elisseeva Human cytotoxic T-lymphoyte responses specific for peptides of the wild -type Wilms' tumor gene (WT1) product Immunogenetics 51 2 2000 99 107
69. H. Dolstra, H. Fredrix, and F. Maas A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia J Exp Med 189 1999 301 308
70. B. De Rijke, H. Fredrix, and A. Zoetbrood Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance to precursor B-ALL-specific immunotherapy Blood 102 2003 2885 2891
71. M.F. Press, C. Cordon-Cardo, and D.J. Slamon Expressionn of the Her2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 7 1990 953 962
72. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
73. S.C. Wang, and M.C. Hung Her-2 overexpression and cancer targeting Semin Oncol 28 2001 115 124
74. H.J. Bòhring, I. Sures, and B. Jallal The receptor tyrosine kinase p185HER2 is expressed on a subset of B lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia Blood 86 5 1995 1916 1923
75. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J Exp Med 181 6 1995 2109 2717
76. G. Peoples, P.S. Goedegebuure, P. Smith, D.C. Linehan, I. Yoshino, and T.J. Eberlein Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER-2/neu derived peptide Proc Natl Acad Sci USA 92 1995 432 436
77. M.R. Muller, and F. Grunebach Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches Clin Cancer Res 3448 2003 3448 3453
78. E. Goulmy Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy Immunol Rev 157 1997 125 140
79. J.M. Den Haan, N.E. Sherman, and E. Blokland Identification of a graft versus host disease-associated human minor histocompatibility antigen Science 268 1995 1476 1480
80. M. De Bueger, A. Bakker, J.J. van Rood, F. van der Woude, and E. Goulmy Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocytes-defined non MHC antigens J Immunol 149 1992 1788 1794
81. T. Mutis, R. Verdijk, E. Schrama, B. Esendam, A. Brand, and E. Goulmy Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens Blood 94 1999 4374 4376
82. B. Kircher, S. Stevanovic, and M. Urbanek Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion Br J Haematol 117 2002 935 939
83. B. Kircher, and M. Wolf Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion J Immunother 27 2 2004 156 160
84. E. Goulmy, R. Schipper, and J. Pool Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation N Engl J Med 334 1996 281
85. L.H. Tseng, M.T. Lin, and J.A. Hansen Correlation between disparity for the minor histocomaptibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation Am Soc Hematol 94 8 1999 2911 2914
86. A.B. Pawlowska, S. Hashino, H. McKenna, B.J. Weigel, P.A. Taylor, and B.R. Blazar In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice Blood 97 2001 1474 1482
87. B.A. Nijmeijer, R. Willemze, and J.H. Falkenburg An animal model for human immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice Blood 100 2002 654 660
88. B.A. Nijmeijer, M.L.J. van Schie, and R. Willemze Purified human CD4+ T cells can erradicate overt human acute lymphoblastic leukaemia as demonstrated in an animal model of human acute leukaemia Bone Marrow Transpl 33 Suppl 1 2004 Abstract Number 669
89. J.H.F. Falkenburg, A.R. Wafelman, and P. Joosten Complete remission of accelerated chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 94 1999 1201 1208